CASE ANALYSIS
Parties:
Novozymes v. Assistant Controller of Patents & Designs
Bench:
The Hon’ble Mr. Justice Senthilkumar Ramamoorthy
Case
Number: CMA (PT) No. 33 of 2023
Citation: 2023 MHC 4261
Introduction
The
case Novozymes v. Assistant Controller of Patents & Designs[1]
revolves around an appeal against the rejection of a patent application by the
Patent Office, Chennai. Novozymes sought to patent phytase variants with
improved thermostability under Indian Patent Application No. 5326/CHENP/2008.
The Assistant Controller rejected the application on grounds of Sections 3(d)
and 3(e) of the Patents Act, 1970, asserting that the invention lacked
significant enhancement of known efficacy and synergy among its composition.
This case highlights critical interpretations of patent eligibility under
Indian law, particularly for biochemical innovations.
Facts
Of The Case
In
Indian Patent Application No. 5326/CHENP/2008, Novozymes sought to patent an
invention titled "Phytase Variants with Improved Thermostability."
The invention involved modifying the amino acid sequence of phytase enzyme (SEQ
ID NO:2) to create variants with enhanced thermostability, aiming to improve
the enzyme’s ability to withstand high temperatures, particularly for
industrial applications like pelletized animal feed. The variants included one
to four amino acid alterations from a list of possible mutations, such as 4P,
46E, 52E, 53V, 76G, 107G, and others. Novozymes also provided a method to test
thermostability by measuring the enzyme’s residual activity after incubating it
at 60°C and 5°C, comparing it to the reference phytase SEQ ID NO:2. The enhanced
thermostability was claimed to make these variants suitable for use at higher
temperatures without denaturation, increasing their industrial utility.
In
addition to the phytase variants, the application included composition claims
(claims 8–11), which combined the thermostable phytase variants with
fat-soluble and water-soluble vitamins and trace minerals to form animal feed
additives intended to provide nutritional benefits.
However,
the Assistant Controller of Patents & Designs rejected the application,
arguing that the invention did not meet patentability requirements under
Sections 3(d) and 3(e) of the Patents Act, 1970. Under Section 3(d), the
Controller contended that the invention was merely a new form of a known
substance (phytase) without significantly enhancing its efficacy. The
Controller argued that enhanced thermostability did not improve phytase’s
primary function—hydrolyzing phytate for phosphorus digestion—beyond what was
already known. The composition claims (claims 8–11) were rejected under Section
3(e) as they were considered a mere admixture of known ingredients, without
synergy or a novel interaction that would warrant patentability.
Novozymes
filed an appeal, challenging the rejection. It argued that the enhanced
thermostability of the variants represented a significant improvement in the
enzyme's efficacy for industrial applications, especially in animal feed
production. The company also contended that the composition claims involved
novel combinations with potential synergistic effects. The appeal raised
critical questions about the interpretation of Section 3(d) in the context of
biochemicals like phytase and the applicability of Section 3(e) to compositions
that utilized these innovations.[2]
Issues
Raised
1. Whether
the term "known substance" under Section 3(d) of the Patents Act
should be interpreted to include biochemical substances like phytase variants
or is it limited to synthetic chemical substances.
2. Whether
the enhanced thermostability of the phytase variants constitutes a
"significant enhancement" of the known efficacy of the enzyme under
Section 3(d).
3. Whether
the composition claims (claims 8–11) are merely an admixture of known
ingredients without the necessary synergy to be patentable under Section 3(e).
4. Whether
the combination of phytase variants with vitamins and minerals in the
composition claims exhibits synergy beyond the sum of its parts, making it
eligible for patent protection under Section 3(e).
Analysis
Of The Issues Raised
1.
Does "known substance" under Section 3(d) include biochemicals like
phytase variants or is it limited to synthetic chemicals?
The
term "known substance" under Section 3(d) raises questions about its
scope—whether it applies only to synthetic chemicals or can extend to
biochemicals. Section 3(d) prohibits patents for new forms of known substances
unless they enhance efficacy, and its Explanation lists examples like salts,
esters, and isomers, which are generally associated with synthetic chemicals.
In
this case, the appellant argued that phytase, being a naturally occurring
enzyme, should not be treated as a synthetic chemical and should not fall
within the Explanation. The Court applied the ejusdem generis principle
and found that the Explanation is indeed limited to synthetic chemicals.
However, the broader substantive provision of Section 3(d), which excludes
certain known substances, applies to all substances, including biochemicals
like phytase.
The
Court distinguished between synthetic and biochemical substances while ensuring
that biochemicals still fall under the ambit of Section 3(d). This
interpretation underscores the law’s intent to balance the exclusion of trivial
inventions with the encouragement of innovation in biotechnology.
2.
Does enhanced thermostability qualify as a "significant enhancement"
of efficacy under Section 3(d)?
Efficacy
under Section 3(d) depends on the context of the invention. For
pharmaceuticals, the Supreme Court in Novartis AG v. Union of India held
that efficacy refers to therapeutic efficacy. In this case, the appellant
claimed that enhanced thermostability—a property allowing phytase to remain
stable at high temperatures—improved the enzyme’s industrial utility in animal
feed production.
The
Assistant Controller argued that enhanced thermostability did not improve the
enzyme’s primary function—catalyzing the hydrolysis of phytate. However, the
Court noted that thermostability is a critical property for the enzyme's
practical use in high-temperature environments like feed pelletization. Without
this property, the enzyme would denature, losing its effectiveness in
industrial applications.
The
Court concluded that thermostability enhances the enzyme’s efficacy by
expanding its utility in real-world conditions, even if it does not directly
improve its enzymatic activity. This interpretation recognizes that efficacy is
not limited to a substance’s core function but also includes enhancements that
make it more applicable or valuable in practical settings.
3.
Do the composition claims (claims 8–11) qualify as patentable under Section
3(e), or are they merely admixtures of known substances?
Section
3(e) excludes compositions from patentability if they are formed by the mere
admixture of known substances without a synergistic effect. The appellant
sought to patent compositions combining thermostable phytase variants with
vitamins and minerals, arguing that these mixtures provided improved
functionality in animal feed.
The
Assistant Controller objected, stating that the compositions lacked synergy, as
the combined ingredients functioned independently and did not produce a result
greater than the sum of their individual effects. The Court agreed, noting that
the appellant had not provided evidence to demonstrate how the combination
created a novel or unexpected benefit.
By
failing to establish a synergistic relationship among the ingredients, the
composition claims fell within the exclusion under Section 3(e). The Court
emphasized that without synergy, the mixture remains an aggregation of
properties, which is insufficient to merit patent protection.
4.
Do the compositions combining phytase variants with vitamins and minerals
demonstrate synergy under Section 3(e)?
Synergy
refers to the phenomenon where the combination of ingredients results in
properties or effects that are greater than the sum of their individual
contributions. The appellant argued that the inclusion of thermostable phytase
variants with vitamins and minerals in animal feed improved bioavailability and
stability.
However,
the Court found no evidence to support this claim. The compositions did not
exhibit any new or unexpected properties beyond those of the individual
ingredients. The Assistant Controller’s position that the compositions were
predictable and lacked inventiveness was upheld.
Without
synergy, the Court concluded that the compositions could not be patented under
Section 3(e). This reinforces the principle that merely combining known
substances without a novel effect does not qualify for patent protection.
Judgment
The
Madras High Court delivered a split judgment on Novozymes' appeal. It ruled
that Section 3(d) could apply to biochemicals like phytase, and the enhanced
thermostability of the phytase variants qualified as a significant enhancement
of efficacy, making the variants patentable. However, under Section 3(e), the
court upheld the rejection of claims 8–11, stating that they were merely
admixtures of known ingredients (phytase, vitamins, and minerals) without
demonstrating synergy or unexpected properties.
The
court partially allowed the appeal: Claims 1–7 (related to the phytase
variants) were deemed patentable, while claims 8–11 (composition claims) were
rejected. The judgment clarified that improvements like thermostability can be
considered enhancements of efficacy, while composition claims require synergy
to be patentable under Section 3(e).[3]
Conclusion
In
Novozymes v. Assistant Controller of Patents & Designs, the Madras
High Court addressed key issues regarding Sections 3(d) and 3(e) of the Patents
Act, 1970, in relation to biotechnological inventions. The court ruled in favor
of Novozymes for the phytase variants, acknowledging that the enhanced
thermostability of the enzyme constituted a significant enhancement of efficacy
under Section 3(d), making the variants patentable. This decision broadens the
interpretation of "efficacy," recognizing that industrial
applications like thermostability, especially in animal feed, qualify as an
enhancement of efficacy, even without improving enzymatic activity.
However,
the court upheld the rejection of composition claims (claims 8–11) under
Section 3(e), ruling that they were simply admixtures of known substances and
lacked synergy. The decision emphasizes the strict criteria for composition
claims, underscoring the need for evidence that the combination creates new or
enhanced properties beyond the sum of the individual ingredients.
Ultimately,
the judgment clarifies the patentability of biotechnological innovations in
India, distinguishing between innovations that enhance industrial functionality
and compositions that require novel interactions to be eligible for protection.
This ruling marks an important step in aligning patent law with advancements in
biotechnology.
[1] Novozymes v. Assistant Controller
of Patents & Designs, CMA (PT) No. 33 of 2023, Indian Patent Application
No. 5326/CHENP/2008 (Madras High Court 2023).
No comments:
Post a Comment